New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
18:29 EDTSFM, HEAR, NUAN, CEMP, GSAT, GERN, MTZ, GALE, ICPT, DSTI, CALL, MM, SMG, HALO, TRAKOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
News For TRAK;DSTI;GSAT;HALO;ICPT;CEMP;SMG;GALE;NUAN;MM;MTZ;HEAR;CALL;GERN;SFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
11:14 EDTNUANRumor: Nuance strength attributed to takeover speculation
Subscribe for More Information
08:07 EDTNUANNuance December volatility elevated into Q4 and outlook
Nuance December call option implied volatility is at 48, January is at 41, April is at 37; compared to its 26-week average of 38 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on November 24.
November 19, 2014
13:10 EDTGSATDISH, Globalstar climb as wireless spectrum bids reportedly jump
Subscribe for More Information
08:58 EDTCEMPCempra files $150M mixed securities shelf
07:50 EDTHEARThree Part Advisors to hold a conference
Subscribe for More Information
07:19 EDTGSATSpectrum auction positive for DISH, Globalstar, says JPMorgan
JPMorgan notes the AWS-3 spectrum auction continued on Tuesday with the aggregate value of licenses with bids at $16.4B, up from Monday's $8.9B and compared to the reserve price of $10.6B that the FCC set for the entire auction. The firm views the rise in prices as negative for telecom carriers that are spending more than expected, namely AT&T (T) and Verizon (VZ), and possibly T-Mobile (TMUS) and US Cellular. It views the prices as positive for independent spectrum owners like DISH (DISH) and Globalstar (GSAT), as well as tower companies American Tower (AMT), SBA Communications (SBAC) and Crown Castle (CCI).
07:09 EDTCEMPJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
06:14 EDTCEMPCempra to receive $16M in BARDA funding for solithromycin pediatric studies
Subscribe for More Information
November 18, 2014
07:37 EDTCEMP, GALEStifel to hold a conference
Subscribe for More Information
07:09 EDTGALEGalena completes enrollment in GALE-401 Phase 2 clinical trial
Galena Biopharma announced the completion of enrollment in the GALE-401, or Anagrelide Controlled Release, Phase 2 Clinical Trial. The Phase 2, clinical proof-of-concept study is treating 18 patients with elevated platelet counts in myeloproliferative neoplasms, or MPNs, including Essential Thrombocythemia, or ET, Polycythemia Vera, or PV, and Primary Myelofibrosis, or PMF. The Phase 2 trial is an open-label, single-arm, multicenter study designed to confirm the platelet-lowering activity of GALE-401 in patients with MPNs, to assess safety and tolerability, and to measure plasma concentrations of anagrelide. The platelet lowering ability of GALE-401 will be measured by the proportion of patients that achieve a complete or partial platelet response for at least four weeks during 24 weeks of treatment. With enrollment complete, patients will now be followed for platelet response while they continue study treatment.
November 17, 2014
11:06 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:32 EDTMTZMasTec upgraded to Buy from Neutral at DA Davidson
Subscribe for More Information
November 16, 2014
17:28 EDTCALLHedge fund manager Tilson sticks with magicJack bet, Bloomberg says
Subscribe for More Information
November 14, 2014
16:21 EDTGERNOn The Fly: Closing Wrap
Subscribe for More Information
15:22 EDTICPTIntercept CEO says company 'very well-positioned' in terms of balance sheet
Subscribe for More Information
12:58 EDTGERNOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTGERNGeron November volatility up on strategic collaboration with Janssen Biotech
Subscribe for More Information
10:00 EDTGERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:12 EDTGERNGeron upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use